08:17 EDT Aldeyra (ALDX) receives Complete Response Letter from FDA for Reproxalap NDA
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALDX:
- Aldeyra options imply 29.5% move in share price post-earnings
- Aldeyra options imply 30.8% move in share price post-earnings
- Aldeyra Therapeutics: Buy Rating Affirmed on Promising Reproxalap and Strategic RASP Market Expansion
- Biotech Alert: Searches spiking for these stocks today
- Aldeyra Therapeutics: Strategic Pipeline Advancements and Financial Stability Drive Buy Rating